Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

7 Aug 2020 14:20

RNS Number : 5433V
ValiRx PLC
07 August 2020
 

VALIRX PLC

("ValiRx", the "Company" or the "Group")

Director Dealing

 

London, UK 7 August 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces the following dealing in the ordinary shares of the Company made by a Director.

 

On 7 August 2020, the Company was informed that Dr Kevin Cox, Non-executive Chairman of the Company, acquired 117,000 ValiRx ordinary shares at an average price of 8.2 pence per share on 7 August 2020, representing approximately 0.22% of the Company's issued ordinary share capital. Following this acquisition, Dr Cox now holds an interest in 250,333 ValiRx ordinary shares, representing approximately 0.46% of the Company's issued ordinary share capital.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

For further information please contact:

ValiRx plc

Tel: +44 (0) 20 7073 2628

www.valirx.com

Suzanne Dilly

Suzanne.Dilly@valirx.com

 

Cairn Financial Advisers LLP(Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 0880

 

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

 

Tel: +44 (0) 20 7469 0930

 

 

 

 

 

 

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Kevin Cox

2

Reason for notification

a.

Position/Status

Non-executive Chairman

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

 

213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrumentIdentification Code

Ordinary Shares

 

 

ISIN: GB00BLH13C52

b.

Nature of the transaction

On market Purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

8.2 pence

 

117,000

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

N/A

 

e.

Date of the transaction

07/08/2020

f.

Place of the transaction

London, UK

 

         

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBXGDIIBGDGGR
Date   Source Headline
26th Jul 20167:00 amRNSIssue of Equity and Bracknor Facility Update
14th Jul 20167:00 amRNSValiSeek Clinical Development Update
12th Jul 201611:58 amRNSResult of GM
7th Jul 20167:00 amRNSSale of TRAC Technology Rights for EUR 0.8 million
27th Jun 20167:00 amRNSNotice of GM
20th Jun 20162:24 pmRNSResult of AGM
7th Jun 20167:00 amRNSQuarterly Update
7th Jun 20167:00 amRNSAppointment of Joint Broker
26th May 20168:00 amRNSPosting of Annual Report & Notice of AGM
19th May 201611:00 amRNSFinal Results
19th May 20167:00 amRNSValiSeek Clinical Development Update
18th May 20164:45 pmRNSConversion of Loan Note, issue of warrant & equity
29th Apr 20167:00 amRNSNotification of US Patent Grant for VAL401
26th Apr 201612:07 pmRNSIssue of Equity
22nd Apr 201610:01 amRNSValiRx to exhibit at the UK Investor Show
19th Apr 20163:32 pmRNSIssue of Equity - conversion of loan note
18th Apr 20165:00 pmRNSIssue of Equity - conversion of loan note
1st Apr 20163:10 pmRNSConversion of Loan Note, issue of warrant & equity
31st Mar 20167:00 amRNSValiRx to exhibit and present at the AACR
21st Mar 20167:00 amRNSConvertible Loan Facility of up to £4.0 million
17th Mar 20167:00 amRNSValiRx engages US investor relations firm
17th Feb 20161:00 pmRNSPlacing to raise £0.5 million
16th Feb 20167:00 amRNSVAL201 Clinical Trial Update
9th Feb 20167:00 amRNSQuarterly Update on Clinical Progress
11th Dec 20159:30 amRNSValiRx to present at Shares Investor Meeting
19th Nov 201510:45 amRNSClinical Phase Development Update
5th Nov 20157:00 amRNSValiRx establishes US office in Boston, MA
27th Oct 20157:00 amRNSCollaboration Agreement
1st Oct 20157:00 amRNSNew Japanese Patent Grant
17th Sep 201512:15 pmRNSHalf Yearly Report
16th Sep 20157:00 amRNSSubscription and Equity Swap
6th Aug 20157:00 amRNSCollaboration and Research Studentship Agreement
21st Jul 20157:00 amRNSVAL201 Clinical Trial Update
16th Jul 20157:00 amRNSValiSeek Clinical Development Update
29th Jun 20157:00 amRNSGrant of options
25th Jun 20157:00 amRNSUPDATE on VAL201 Clinical Trial
3rd Jun 20157:00 amRNSChange of Adviser
27th May 201511:22 amRNSStmnt re Share Price Movement
15th May 20152:45 pmRNSResult of AGM and Capital Reorganisation
14th May 20153:50 pmRNSNotification of US Patent Grant Allowance reVAL401
14th May 20157:00 amRNSValiSeek Development Update
7th May 20157:00 amRNSRe Contract
30th Apr 20157:00 amRNSValiRX to attend 2015 BIO International Convention
22nd Apr 20157:00 amRNSNotice of AGM and Proposed Capital Reorganisation
16th Apr 20157:00 amRNSFinal Results
17th Mar 20157:00 amRNSIssue of equity to Cancer Research Technology Ltd
6th Mar 20157:00 amRNSPlacing to raise GBP800,000
26th Feb 20157:00 amRNSNew Endometriosis Patent Grant
24th Feb 20157:00 amRNSSuccessful 1st Results from VAL201 Clinical Trial
11th Feb 20157:00 amRNSNew European Patent Grant

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.